Obesity-Pipeline Review, H2 2016

Obesity-Pipeline Review, H2 2016


  • Products Id :- GMDHC8621IDB
  • |
  • Pages: 537
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Global Markets Direct’s, ‘Obesity - Pipeline Review, H2 2016’, provides an overview of the Obesity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

 

Scope

 

The report provides a snapshot of the global therapeutic landscape of Obesity

The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects

The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Obesity

 

Reasons to Buy

 

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Obesity

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 7

Obesity Overview 8

Therapeutics Development 9

Obesity - Therapeutics under Development by Companies 11

Obesity - Therapeutics under Investigation by Universities/Institutes 21

Obesity - Pipeline Products Glance 24

Obesity - Products under Development by Companies 28

Obesity - Products under Investigation by Universities/Institutes 40

Obesity - Companies Involved in Therapeutics Development 44

Obesity - Therapeutics Assessment 144

Drug Profiles 166

Obesity - Dormant Projects 468

Obesity - Discontinued Products 493

Obesity - Product Development Milestones 500

Appendix 509

List of Figures

Number of Products under Development for Obesity, H2 2016 36

Number of Products under Development for Obesity - Comparative Analysis, H2 2016 37

Number of Products under Development by Companies, H2 2016 38

Number of Products under Investigation by Universities/Institutes, H2 2016 48

Comparative Analysis by Late Stage Development, H2 2016 51

Comparative Analysis by Clinical Stage Development, H2 2016 52

Comparative Analysis by Early Stage Products, H2 2016 53

Assessment by Monotherapy Products, H2 2016 171

Assessment by Combination Products, H2 2016 172

Number of Products by Top 10 Targets, H2 2016 173

Number of Products by Stage and Top 10 Targets, H2 2016 173

Number of Products by Top 10 Mechanism of Actions, H2 2016 181

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 181

Number of Products by Routes of Administration, H2 2016 189

Number of Products by Stage and Routes of Administration, H2 2016 189

Number of Products by Top 10 Molecule Types, H2 2016 191

Number of Products by Stage and Top 10 Molecule Types, H2 2016 191

List of Tables

Number of Products under Development for Obesity, H2 2016 36

Number of Products under Development for Obesity - Comparative Analysis, H2 2016 37

Number of Products under Development by Companies, H2 2016 39

Number of Products under Development by Companies, H2 2016 (Contd..1) 40

Number of Products under Development by Companies, H2 2016 (Contd..2) 41

Number of Products under Development by Companies, H2 2016 (Contd..3) 42

Number of Products under Development by Companies, H2 2016 (Contd..4) 43

Number of Products under Development by Companies, H2 2016 (Contd..5) 44

Number of Products under Development by Companies, H2 2016 (Contd..6) 45

Number of Products under Development by Companies, H2 2016 (Contd..7) 46

Number of Products under Development by Companies, H2 2016 (Contd..8) 47

Number of Products under Investigation by Universities/Institutes, H2 2016 48

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 50

Comparative Analysis by Late Stage Development, H2 2016 51

Comparative Analysis by Clinical Stage Development, H2 2016 52

Comparative Analysis by Early Stage Development, H2 2016 53

Comparative Analysis by Unknown Stage Development, H2 2016 54

Products under Development by Companies, H2 2016 55

Products under Development by Companies, H2 2016 (Contd..1) 56

Products under Development by Companies, H2 2016 (Contd..2) 57

Products under Development by Companies, H2 2016 (Contd..3) 58

Products under Development by Companies, H2 2016 (Contd..4) 59

Products under Development by Companies, H2 2016 (Contd..5) 60

Products under Development by Companies, H2 2016 (Contd..6) 61

Products under Development by Companies, H2 2016 (Contd..7) 62

Products under Development by Companies, H2 2016 (Contd..8) 63

Products under Development by Companies, H2 2016 (Contd..9) 64

Products under Development by Companies, H2 2016 (Contd..10) 65

Products under Development by Companies, H2 2016 (Contd..11) 66

Products under Investigation by Universities/Institutes, H2 2016 67

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 68

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 69

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 70

Obesity - Pipeline by Abeome Corporation, H2 2016 71

Obesity - Pipeline by Acylin Therapeutics Inc, H2 2016 72

Obesity - Pipeline by Advinus Therapeutics Ltd, H2 2016 73

Obesity - Pipeline by Aegis Therapeutics, LLC, H2 2016 74

Obesity - Pipeline by Akron Molecules AG, H2 2016 75

Obesity - Pipeline by Alize Pharma SAS, H2 2016 76

Obesity - Pipeline by Amabiotics SAS, H2 2016 77

Obesity - Pipeline by Amgen Inc., H2 2016 78

Obesity - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016 79

Obesity - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 80

Obesity - Pipeline by AstraZeneca Plc, H2 2016 81

Obesity - Pipeline by Asubio Pharma Co., Ltd., H2 2016 82

Obesity - Pipeline by Athersys, Inc., H2 2016 83

Obesity - Pipeline by Biophytis SAS, H2 2016 84

Obesity - Pipeline by BioRestorative Therapies, Inc., H2 2016 85

Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2016 86

Obesity - Pipeline by Braasch Biotech LLC, H2 2016 87

Obesity - Pipeline by C3 Jian, Inc, H2 2016 88

Obesity - Pipeline by Carmot Therapeutics Inc, H2 2016 89

Obesity - Pipeline by Chronos Therapeutics Limited, H2 2016 90

Obesity - Pipeline by CohBar, Inc., H2 2016 91

Obesity - Pipeline by CoMentis, Inc., H2 2016 92

Obesity - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 93

Obesity - Pipeline by Corium International, Inc., H2 2016 94

Obesity - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 95

Obesity - Pipeline by Diabetica Limited, H2 2016 96

Obesity - Pipeline by DiscoveryBiomed, Inc., H2 2016 97

Obesity - Pipeline by Eli Lilly and Company, H2 2016 98

Obesity - Pipeline by Esperion Therapeutics, Inc., H2 2016 99

Obesity - Pipeline by Eternygen GmbH, H2 2016 100

Obesity - Pipeline by Evotec AG, H2 2016 101

Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 102

Obesity - Pipeline by FibroGen Inc, H2 2016 103

Obesity - Pipeline by Galenea Corp., H2 2016 104

Obesity - Pipeline by Gila Therapeutics Inc, H2 2016 105

Obesity - Pipeline by Gilead Sciences, Inc., H2 2016 106

Obesity - Pipeline by GlaxoSmithKline Plc, H2 2016 107

Obesity - Pipeline by GTx, Inc., H2 2016 108

Obesity - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 109

Obesity - Pipeline by Handok Inc., H2 2016 110

Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 111

Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 112

Obesity - Pipeline by Immungenetics AG, H2 2016 113

Obesity - Pipeline by Intarcia Therapeutics, Inc., H2 2016 114

Obesity - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 115

Obesity - Pipeline by Ixchel Pharma, LLC, H2 2016 116

Obesity - Pipeline by Jenrin Discovery, Inc., H2 2016 117

ity - Pipeline by Johnson & Johnson, H2 2016 118

Obesity - Pipeline by Lead Discovery Center GmbH, H2 2016 120

Obesity - Pipeline by Leading BioSciences, Inc., H2 2016 121

Obesity - Pipeline by LEO Pharma A/S, H2 2016 122

Obesity - Pipeline by LG Life Science LTD., H2 2016 123

Obesity - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 124

Obesity - Pipeline by M Pharmaceutical Inc., H2 2016 125

Obesity - Pipeline by Magnus Life Ltd, H2 2016 126

Obesity - Pipeline by MAKScientific, LLC, H2 2016 127

Obesity - Pipeline by MedImmune LLC, H2 2016 128

Obesity - Pipeline by Merck & Co., Inc., H2 2016 129

Obesity - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016 130

Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 131

Obesity - Pipeline by NeuroNano Pharma Inc, H2 2016 132

Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 133

Obesity - Pipeline by NIBEC, H2 2016 134

Obesity - Pipeline by Nordic Bioscience A/S, H2 2016 135

Obesity - Pipeline by Novo Nordisk A/S, H2 2016 136

Obesity - Pipeline by ObeTherapy Biotechnology, H2 2016 137

Obesity - Pipeline by Ogeda SA, H2 2016 138

Obesity - Pipeline by Omeros Corporation, H2 2016 139

Obesity - Pipeline by OPKO Biologics Ltd, H2 2016 140

Obesity - Pipeline by OPKO Health, Inc., H2 2016 141

Obesity - Pipeline by Orbis Biosciences Inc, H2 2016 142

Obesity - Pipeline by Orexigen Therapeutics, Inc., H2 2016 143

Obesity - Pipeline by Pfizer Inc., H2 2016 144

Obesity - Pipeline by PharmaIN Corporation, H2 2016 145

Obesity - Pipeline by Poxel SA, H2 2016 146

Obesity - Pipeline by Progenra, Inc., H2 2016 147

Obesity - Pipeline by Prometheon Pharma, LLC, H2 2016 148

Obesity - Pipeline by ReCyte Therapeutics, Inc., H2 2016 149

Obesity - Pipeline by Renova Therapeutics Inc, H2 2016 150

Obesity - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 151

Obesity - Pipeline by Saniona AB, H2 2016 152

Obesity - Pipeline by Sanofi, H2 2016 153

Obesity - Pipeline by Selvita S.A., H2 2016 154

Obesity - Pipeline by Seoul Pharma Co., Ltd., H2 2016 155

Obesity - Pipeline by Shionogi & Co., Ltd., H2 2016 156

- Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016 157

Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 159

Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 160

Obesity - Pipeline by Toray Industries, Inc., H2 2016 161

Obesity - Pipeline by Umecrine AB, H2 2016 162

Obesity - Pipeline by Vicore Pharma AB, H2 2016 163

Obesity - Pipeline by Viking Therapeutics, Inc., H2 2016 164

Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016 165

Obesity - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016 166

Obesity - Pipeline by XL-protein GmbH, H2 2016 167

Obesity - Pipeline by Yuyu Pharma, Inc., H2 2016 168

1`Obesity - Pipeline by Zafgen Inc., H2 2016 169

Obesity - Pipeline by Zealand Pharma A/S, H2 2016 170

Assessment by Monotherapy Products, H2 2016 171

Assessment by Combination Products, H2 2016 172

Number of Products by Stage and Target, H2 2016 174

Number of Products by Stage and Mechanism of Action, H2 2016 182

Number of Products by Stage and Route of Administration, H2 2016 190

Number of Products by Stage and Molecule Type, H2 2016 192

Obesity - Dormant Projects, H2 2016 495

Obesity - Dormant Projects (Contd..1), H2 2016 496

Obesity - Dormant Projects (Contd..2), H2 2016 497

Obesity - Dormant Projects (Contd..3), H2 2016 498

Obesity - Dormant Projects (Contd..4), H2 2016 499

Obesity - Dormant Projects (Contd..5), H2 2016 500

Obesity - Dormant Projects (Contd..6), H2 2016 501

Obesity - Dormant Projects (Contd..7), H2 2016 502

Obesity - Dormant Projects (Contd..8), H2 2016 503

Obesity - Dormant Projects (Contd..9), H2 2016 504

Obesity - Dormant Projects (Contd..10), H2 2016 505

Obesity - Dormant Projects (Contd..11), H2 2016 506

Obesity - Dormant Projects (Contd..12), H2 2016 507

Obesity - Dormant Projects (Contd..13), H2 2016 508

Obesity - Dormant Projects (Contd..14), H2 2016 509

Obesity - Dormant Projects (Contd..15), H2 2016 510

Obesity - Dormant Projects (Contd..16), H2 2016 511

Obesity - Dormant Projects (Contd..17), H2 2016 512

Obesity - Dormant Projects (Contd..18), H2 2016 513

Obesity - Dormant Projects (Contd..19), H2 2016 514

Obesity - Dormant Projects (Contd..20), H2 2016 515

Obesity - Dormant Projects (Contd..21), H2 2016 516

Obesity - Dormant Projects (Contd..22), H2 2016 517

Obesity - Dormant Projects (Contd..23), H2 2016 518

Obesity - Dormant Projects (Contd..24), H2 2016 519

Obesity - Discontinued Products, H2 2016 520

Obesity - Discontinued Products (Contd..1), H2 2016 521

Obesity - Discontinued Products (Contd..2), H2 2016 522

Obesity - Discontinued Products (Contd..3), H2 2016 523

Obesity - Discontinued Products (Contd..4), H2 2016 524

Obesity - Discontinued Products (Contd..5), H2 2016 525

Obesity - Discontinued Products (Contd..6), H2 2016 526

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Abeome Corporation, Acylin Therapeutics Inc, Advinus Therapeutics Ltd, Aegis Therapeutics, LLC, Akron Molecules AG, Alize Pharma SAS, Amabiotics SAS, Amgen Inc., Aoxing Pharmaceutical Company, Inc, Arena Pharmaceuticals, Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Athersys, Inc., Biophytis SAS, BioRestorative Therapies, Inc., Boehringer Ingelheim GmbH, Braasch Biotech LLC, C3 Jian, Inc, Carmot Therapeutics Inc, Chronos Therapeutics Limited, CohBar, Inc., CoMentis, Inc., Connexios Life Sciences Pvt. Ltd., Corium International, Inc., Daiichi Sankyo Company, Limited, Diabetica Limited, DiscoveryBiomed, Inc., Eli Lilly and Company, Esperion Therapeutics, Inc., Eternygen GmbH, Evotec AG, F. Hoffmann-La Roche Ltd., FibroGen Inc, Galenea Corp., Gila Therapeutics Inc, Gilead Sciences, Inc., GlaxoSmithKline Plc, GTx, Inc., HanAll Biopharma Co., Ltd., Handok Inc., Hanmi Pharmaceuticals, Co. Ltd., Hyundai Pharmaceutical Co., Ltd., Immungenetics AG, Intarcia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Ixchel Pharma, LLC, Jenrin Discovery, Inc., Johnson & Johnson, Kowa Company, Ltd., Lead Discovery Center GmbH, Leading BioSciences, Inc., LEO Pharma A/S, LG Life Science LTD., Lotus Pharmaceutical Co., Ltd., M Pharmaceutical Inc., Magnus Life Ltd, MAKScientific, LLC, MedImmune LLC, Merck & Co., Inc., Mitochon Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, NeuroNano Pharma Inc, NGM Biopharmaceuticals, Inc., NIBEC, Nordic Bioscience A/S, Novo Nordisk A/S, ObeTherapy Biotechnology, Ogeda SA, Omeros Corporation, OPKO Biologics Ltd, OPKO Health, Inc., Orbis Biosciences Inc, Orexigen Therapeutics, Inc., Pfizer Inc., PharmaIN Corporation, Poxel SA, Progenra, Inc., Prometheon Pharma, LLC, ReCyte Therapeutics, Inc., Renova Therapeutics Inc, Reviva Pharmaceuticals Inc., Saniona AB, Sanofi, Selvita S.A., Seoul Pharma Co., Ltd., Shionogi & Co., Ltd., Sinil Pharmaceutical Co., Ltd, Sorrento Therapeutics Inc, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Toray Industries, Inc., Umecrine AB, Vicore Pharma AB, Viking Therapeutics, Inc., WhanIn Pharmaceutical Co., Ltd., Xenetic Biosciences (UK) Limited, XL-protein GmbH, Yuyu Pharma, Inc., Zafgen Inc., Zealand Pharma A/S

select a license

Single User License
USD 2500 INR 179700
Site License
USD 5000 INR 359400
Corporate User License
USD 7500 INR 539100

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com